Related Experiment Video
Updated: Feb 11, 2026

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
Published on: November 8, 2016
Recent Advances in Drug Development and Regulatory Science in China
11 BARDS Methodology Research, UG1D016, Merck Research Laboratories, Upper Gwynedd, PA, USA.
Abstract:
As the second largest pharmaceutical market with a great potential for future growth, China has drawn much attention from the global pharmaceutical community. With an increasing government investment in biomedical research, the domestic biopharmaceutical (biotechnological) companies in China are turning their attention to the development of innovative medicines and targeting the global market. To introduce innovative products to Chinese patients sooner, to improve the efficiency of its review and approval processes, and to harmonize its regulatory science with international standards, the China Food and Drug Administration (CFDA) has initiated a series of major changes to its policies and regulations. This paper presents a snapshot of China's pharmaceutical market, and research and development status, and introduces technical guidelines pertaining to clinical trials and new drug applications. The recent wave of ground-breaking reforms in CFDA's regulatory science is discussed. Examples of clinical trials and new drug applications are provided throughout the discussion.
Related Concept Videos
Cis-regulatory Sequences
Cis-regulatory Sequences
Drug Control Governance: Regulatory Bodies and Their Impact
Psychology as a Science
The scientific method in psychology involves six critical steps: making observations, formulating hypotheses, conducting tests, analyzing...
Overview of Biostatistics in Health Sciences
Global Regulatory Systems

